{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:00:20Z","timestamp":1794081620475,"version":"4.8.0"},"reference-count":118,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Medications are a common cause of AKI, especially for patients admitted to hospital wards and the intensive care unit. Although drug-related kidney injury occurs through different mechanisms, this review will focus on three specific types of tubulointerstitial injury. Direct acute tubular injury develops from several medications, which are toxic to various cellular functions. Their excretory pathways through the proximal tubules contribute further to AKI. Drug-induced AKI may also develop through induction of inflammation within the tubulointerstitium. Medications can elicit a T cell\u2013mediated immune response that promotes the development of acute interstitial nephritis leading to AKI. Although less common, a third pathway to kidney injury results from the insolubility of drugs in the urine leading to their precipitation as crystals within distal tubular lumens, causing a crystalline-related AKI. Intratubular obstruction, direct tubular injury, and localized inflammation lead to AKI. Clinicians should be familiar with the pathogenesis and clinical-pathologic manifestations of these forms of kidney injury. Prevention and treatment of AKI relies on understanding the pathogenesis and judiciously using these agents in settings where AKI risk is high.<\/jats:p>","DOI":"10.2215\/cjn.11290821","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:20:14Z","timestamp":1646911214000},"page":"1220-1233","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":354,"title":["Drug-Induced Acute Kidney Injury"],"prefix":"10.2215","volume":"17","author":[{"given":"Mark A.","family":"Perazella","sequence":"first","affiliation":[{"name":"Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Veteran\u2019s Affairs Medical Center, West Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell H.","family":"Rosner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1523-1755.2004.00927.x","article-title":"Spectrum of acute renal failure in the intensive care unit: The PICARD experience","volume":"66","author":"Mehta","year":"2004","journal-title":"Kidney Int"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med"},{"issue":"2","key":"B3-20241015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000510455","article-title":"Drug-induced hospital-acquired acute kidney injury in China: A multicenter cross-sectional survey","volume":"7","author":"Liu","year":"2021","journal-title":"Kidney Dis (Basel)"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2215\/CJN.00150118","article-title":"Pharmacology behind common drug nephrotoxicities","volume":"13","author":"Perazella","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/QAD.0b013e3283262a64","article-title":"Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir","volume":"23","author":"Labarga","year":"2009","journal-title":"AIDS"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1086\/598507","article-title":"Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: A pharmacogenetic study","volume":"48","author":"Rodr\u00edguez-N\u00f3voa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","article-title":"Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs","volume":"20","author":"Cihlar","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nrd1201","article-title":"Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective","volume":"2","author":"Lewis","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 2","key":"B11-20241015","doi-asserted-by":"crossref","first-page":"M47","DOI":"10.1177\/135965350501002S05","article-title":"Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria","volume":"10","author":"Moyle","year":"2005","journal-title":"Antivir Ther"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"14711","DOI":"10.1021\/bi035596s","article-title":"Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase","volume":"42","author":"Lee","year":"2003","journal-title":"Biochemistry"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2009.142","article-title":"The nephrotoxic effects of HAART","volume":"5","author":"Izzedine","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/QAD.0b013e3283313f54","article-title":"Tenofovir\/probenecid combination in HIV\/HBV-coinfected patients: How to escape Fanconi syndrome recurrence?","volume":"24","author":"Izzedine","year":"2010","journal-title":"AIDS"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/ki.2008.252","article-title":"Rosiglitazone reverses tenofovir-induced nephrotoxicity","volume":"74","author":"Lib\u00f3rio","year":"2008","journal-title":"Kidney Int"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities","volume":"78","author":"Herlitz","year":"2010","journal-title":"Kidney Int"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/368314","article-title":"Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"36","author":"Karras","year":"2003","journal-title":"Clin Infect Dis"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.phrs.2010.04.004","article-title":"Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it?","volume":"62","author":"Balakumar","year":"2010","journal-title":"Pharmacol Res"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ki.1991.76","article-title":"Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicity","volume":"39","author":"Olbricht","year":"1991","journal-title":"Kidney Int"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"F337","DOI":"10.1152\/ajprenal.2001.281.2.F337","article-title":"Role of megalin in renal handling of aminoglycosides","volume":"281","author":"Nagai","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2016060606","article-title":"Megalin blockade with cilastatin suppresses drug-induced nephrotoxicity","volume":"28","author":"Hori","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/sj.bjp.0701403","article-title":"Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: Dose-response relationship and role of renal tubular injury","volume":"122","author":"Parsons","year":"1997","journal-title":"Br J Pharmacol"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.lfs.2007.11.014","article-title":"Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues","volume":"82","author":"Banday","year":"2008","journal-title":"Life Sci"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/ki.1981.19","article-title":"Pathophysiology of altered glomerular function in aminoglycoside-treated rats","volume":"19","author":"Schor","year":"1981","journal-title":"Kidney Int"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1289\/ehp.8457293","article-title":"Renal ultrastructural and biochemical injuries induced by aminoglycosides","volume":"57","author":"Cojocel","year":"1984","journal-title":"Environ Health Perspect"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1983.205","article-title":"Reduction of renal blood flow and proximal bicarbonate reabsorption in rats by gentamicin","volume":"24","author":"Klotman","year":"1983","journal-title":"Kidney Int"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/ki.1988.83","article-title":"Aminoglycoside nephrotoxicity","volume":"33","author":"Humes","year":"1988","journal-title":"Kidney Int"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000440867","article-title":"Acute kidney injury and renal recovery with the use of aminoglycosides: A large retrospective study","volume":"131","author":"Paquette","year":"2015","journal-title":"Nephron"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000513742","article-title":"Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: A comprehensive review","volume":"52","author":"Blair","year":"2021","journal-title":"Am J Nephrol"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2016080867","article-title":"Vancomycin-associated cast nephropathy","volume":"28","author":"Luque","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bcp.2007.03.004","article-title":"Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity","volume":"74","author":"Yokoo","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-07-4793","article-title":"Interaction of cisplatin with the human organic cation transporter 2","volume":"14","author":"Filipski","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B36-20241015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2133\/dmpk.23.243","article-title":"Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences","volume":"23","author":"Choi","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"B37-20241015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/cts.12480","article-title":"Identification of OAT1\/OAT3 as contributors to cisplatin toxicity","volume":"10","author":"Hu","year":"2017","journal-title":"Clin Transl Sci"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: A review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J Nephrol"},{"key":"B39-20241015","first-page":"1663","article-title":"Cisplatin and platinum drugs at the molecular level. (Review)","volume":"10","author":"Boulikas","year":"2003","journal-title":"Oncol Rep"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0167-4781(02)00535-3","article-title":"The interaction of cisplatin and analogues with DNA in reconstituted chromatin","volume":"1579","author":"Galea","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"B41-20241015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-\u03b1 mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J Clin Invest"},{"key":"B42-20241015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1681\/ASN.2005010102","article-title":"A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B43-20241015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.ki.5002242","article-title":"Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-\u03b1 produced by renal parenchymal cells","volume":"72","author":"Zhang","year":"2007","journal-title":"Kidney Int"},{"key":"B44-20241015","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","article-title":"Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin","volume":"36","author":"Motwani","year":"2018","journal-title":"J Clin Oncol"},{"key":"B45-20241015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1987.5.2.304","article-title":"Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity","volume":"5","author":"Reece","year":"1987","journal-title":"J Clin Oncol"},{"key":"B46-20241015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9","article-title":"Platinum organ toxicity and possible prevention in patients with testicular cancer","volume":"83","author":"Hartmann","year":"1999","journal-title":"Int J Cancer"},{"key":"B47-20241015","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B48-20241015","first-page":"375","article-title":"Cis-platinum and distal renal tubule toxicity","volume":"98","author":"Swainson","year":"1985","journal-title":"N Z Med J"},{"key":"B49-20241015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-108-1-21","article-title":"Renal salt wasting in patients treated with cisplatin","volume":"108","author":"Hutchison","year":"1988","journal-title":"Ann Intern Med"},{"key":"B50-20241015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.7326\/0003-4819-90-6-929","article-title":"Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin","volume":"90","author":"Schilsky","year":"1979","journal-title":"Ann Intern Med"},{"key":"B51-20241015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/taap.1994.1241","article-title":"Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney","volume":"129","author":"Zamlauski-Tucker","year":"1994","journal-title":"Toxicol Appl Pharmacol"},{"key":"B52-20241015","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1158\/0008-5472.CAN-06-1043","article-title":"Ifosfamide-induced nephrotoxicity: Mechanism and prevention","volume":"66","author":"Nissim","year":"2006","journal-title":"Cancer Res"},{"key":"B53-20241015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157488506775268515","article-title":"Clinical pharmacology of cyclophosphamide and ifosfamide","volume":"1","author":"Zhang","year":"2006","journal-title":"Curr Drug Ther"},{"key":"B54-20241015","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2008.17.5257","article-title":"Long-term evaluation of ifosfamide-related nephrotoxicity in children","volume":"27","author":"Oberlin","year":"2009","journal-title":"J Clin Oncol"},{"key":"B55-20241015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/imj.15229","article-title":"Novel renal biomarkers of acute kidney injury and their implications","volume":"51","author":"Bellomo","year":"2021","journal-title":"Intern Med J"},{"key":"B56-20241015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrneph.2010.71","article-title":"Drug-induced acute interstitial nephritis","volume":"6","author":"Perazella","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B57-20241015","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2215\/CJN.01330213","article-title":"Utility of urine eosinophils in the diagnosis of acute interstitial nephritis","volume":"8","author":"Muriithi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B58-20241015","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1523-1755.2004.00831.x","article-title":"The Italian experience of the national registry of renal biopsies","volume":"66","author":"Gesualdo","year":"2004","journal-title":"Kidney Int"},{"key":"B59-20241015","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B60-20241015","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2215\/CJN.07630717","article-title":"Drug-induced acute interstitial nephritis","volume":"12","author":"Moledina","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B61-20241015","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2215\/CJN.12001018","article-title":"Treatment of drug-induced acute tubulointerstitial nephritis: The search for better evidence","volume":"13","author":"Moledina","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B62-20241015","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/0002-9343(92)90181-A","article-title":"Acute interstitial nephritis due to omeprazole","volume":"93","author":"Ruffenach","year":"1992","journal-title":"Am J Med"},{"key":"B63-20241015","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ki.2014.294","article-title":"Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly","volume":"87","author":"Muriithi","year":"2015","journal-title":"Kidney Int"},{"key":"B64-20241015","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.9778\/cmajo.20140074","article-title":"Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study","volume":"3","author":"Antoniou","year":"2015","journal-title":"CMAJ Open"},{"key":"B65-20241015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1440-1797.2006.00651.x","article-title":"Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases","volume":"11","author":"Simpson","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"B66-20241015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"key":"B67-20241015","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1681\/ASN.2015121377","article-title":"Proton pump inhibitors and risk of incident CKD and progression to ESRD","volume":"27","author":"Xie","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B68-20241015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12882-016-0325-4","article-title":"Proton pump inhibitors are associated with increased risk of development of chronic kidney disease","volume":"17","author":"Arora","year":"2016","journal-title":"BMC Nephrol"},{"key":"B69-20241015","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1681\/ASN.2016020192","article-title":"Proton pump inhibitors and CKD","volume":"27","author":"Moledina","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B70-20241015","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"B71-20241015","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B72-20241015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: What do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"B73-20241015","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","article-title":"Biopsy-proven acute interstitial nephritis, 1993-2011: A case series","volume":"64","author":"Muriithi","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B74-20241015","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.ajkd.2012.05.002","article-title":"Urinary sediment findings in acute interstitial nephritis","volume":"60","author":"Fogazzi","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B75-20241015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000501207","article-title":"Differentiating acute interstitial nephritis from acute tubular injury: A challenge for clinicians","volume":"143","author":"Moledina","year":"2019","journal-title":"Nephron"},{"key":"B76-20241015","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2215\/CJN.08620813","article-title":"Urinary eosinophils in AIN: Farewell to an old biomarker?","volume":"8","author":"Perazella","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B77-20241015","doi-asserted-by":"crossref","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"key":"B78-20241015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4049\/jimmunol.1800237","article-title":"HLA-DQA1, -DQB1, and -DRB1 alleles associated with acute tubulointerstitial nephritis in a Chinese population: A single-center cohort study","volume":"201","author":"Jia","year":"2018","journal-title":"J Immunol"},{"key":"B79-20241015","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1681\/ASN.2006050418","article-title":"Involvement of drug-specific T cells in acute drug-induced interstitial nephritis","volume":"17","author":"Spanou","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B80-20241015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clim.2019.06.005","article-title":"Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury","volume":"205","author":"Sun","year":"2019","journal-title":"Clin Immunol"},{"key":"B81-20241015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/nep.12226","article-title":"Omeprazole-induced acute interstitial nephritis: A possible Th1-Th17-mediated injury?","volume":"19","author":"Berney-Meyer","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"B82-20241015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5414\/CN108254","article-title":"The role of type I hypersensitivity reaction and IgE-mediated mast cell activation in acute interstitial nephritis","volume":"84","author":"Zand","year":"2015","journal-title":"Clin Nephrol"},{"key":"B83-20241015","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2215\/CJN.01390118","article-title":"Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis","volume":"13","author":"Fernandez-Juarez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B84-20241015","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1440-1797.2012.01648.x","article-title":"Acute tubulointerstitial nephritis, treatment with steroid and impact on renal outcomes","volume":"17","author":"Raza","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"B85-20241015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/sj.ki.5002776","article-title":"Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis","volume":"73","author":"Gonz\u00e1lez","year":"2008","journal-title":"Kidney Int"},{"key":"B86-20241015","first-page":"233","article-title":"Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids","volume":"10","author":"Prendecki","year":"2017","journal-title":"Clin Kidney J"},{"key":"B87-20241015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/qjmed\/hcu236","article-title":"Acute tubulointerstitial nephritis in Scotland","volume":"108","author":"Valluri","year":"2015","journal-title":"QJM"},{"key":"B88-20241015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12882-019-1277-2","article-title":"Effect of steroids and relevant cytokine analysis in acute tubulointerstitial nephritis","volume":"20","author":"Yun","year":"2019","journal-title":"BMC Nephrol"},{"key":"B89-20241015","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1093\/ndt\/gfh485","article-title":"Acute interstitial nephritis: Clinical features and response to corticosteroid therapy","volume":"19","author":"Clarkson","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B90-20241015","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/1319-2442.235171","article-title":"Drug-induced acute interstitial nephritis: prospective randomized trial comparing oral steroids and high-dose intravenous pulse steroid therapy in guiding the treatment of this condition","volume":"29","author":"Chowdry","year":"2018","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B91-20241015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/08860229609052779","article-title":"Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis","volume":"18","author":"Bhaumik","year":"1996","journal-title":"Ren Fail"},{"key":"B92-20241015","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/ndt\/gfr500","article-title":"Acute and chronic nephropathy induced by fluindione must be addressed","volume":"27","author":"Cam","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B93-20241015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.08211109","article-title":"Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis","volume":"5","author":"Parkhie","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B94-20241015","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/ndt\/gfaa169","article-title":"Urine interleukin-9 and tumor necrosis factor-\u03b1 for prognosis of human acute interstitial nephritis","volume":"36","author":"Moledina","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"B95-20241015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ckj\/sfz097","article-title":"Inflammatory leucocyte infiltrates are associated with recovery in biopsy-proven acute interstitial nephritis: A 20-year registry-based case series","volume":"12","author":"Wendt","year":"2019","journal-title":"Clin Kidney J"},{"key":"B96-20241015","doi-asserted-by":"crossref","first-page":"1877415","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"OncoImmunology"},{"key":"B97-20241015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.7.2.147","article-title":"Drug-induced crystal nephropathy: An update","volume":"7","author":"Yarlagadda","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"B98-20241015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40265-017-0853-7","article-title":"Drug-induced kidney stones and crystalline nephropathy: Pathophysiology, prevention and treatment","volume":"78","author":"Daudon","year":"2018","journal-title":"Drugs"},{"key":"B99-20241015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/ckj\/sfu105","article-title":"Crystalline-induced kidney disease: A case for urine microscopy","volume":"8","author":"Luciano","year":"2015","journal-title":"Clin Kidney J"},{"key":"B100-20241015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.5858\/arpa.2011-0565-RA","article-title":"Crystalline nephropathies","volume":"136","author":"Herlitz","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"B101-20241015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/MCC.0000000000000653","article-title":"Drug-induced acute kidney injury: Diverse mechanisms of tubular injury","volume":"25","author":"Perazella","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"B102-20241015","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2018.07.012","article-title":"Urine sediment examination in the diagnosis and management of kidney disease: Core curriculum 2019","volume":"73","author":"Cavanaugh","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B103-20241015","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin Nephrol"},{"key":"B104-20241015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-008-0772-0","article-title":"Renal dysfunction during and after high-dose methotrexate","volume":"63","author":"Green","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"B105-20241015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.semdp.2020.02.002","article-title":"A diagnostician\u2019s field guide to crystalline nephropathies","volume":"37","author":"Nicholas Cossey","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"B106-20241015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/nep.12428","article-title":"Sulfadiazine-induced crystal nephropathy: A new \u2018old\u2019 problem","volume":"20","author":"Slade","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"B107-20241015","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1001\/archinte.1990.00390220113023","article-title":"Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome","volume":"150","author":"Simon","year":"1990","journal-title":"Arch Intern Med"},{"key":"B108-20241015","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1053\/ajkd.2001.27732","article-title":"Indinavir nephropathy revisited: A pattern of insidious renal failure with identifiable risk factors","volume":"38","author":"Reilly","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B109-20241015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-127-2-199707150-00004","article-title":"Crystalluria and urinary tract abnormalities associated with indinavir","volume":"127","author":"Kopp","year":"1997","journal-title":"Ann Intern Med"},{"key":"B110-20241015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.ackd.2018.12.001","article-title":"The changing face of human immunodeficiency virus-mediated kidney disease","volume":"26","author":"Sury","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"B111-20241015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ckj\/sfv015","article-title":"Atazanavir nephrotoxicity","volume":"8","author":"Hara","year":"2015","journal-title":"Clin Kidney J"},{"key":"B112-20241015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2018.11.014","article-title":"Severe acute kidney injury and double tubulopathy due to dual toxicity caused by combination antiretroviral therapy","volume":"4","author":"Soto","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B113-20241015","doi-asserted-by":"crossref","first-page":"292953","DOI":"10.1155\/2013\/292953","article-title":"Nephrolithiasis: Molecular mechanism of renal stone formation and the critical role played by modulators","volume":"2013","author":"Aggarwal","year":"2013","journal-title":"BioMed Res Int"},{"key":"B114-20241015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000487671","article-title":"Novel insights into crystal-induced kidney injury","volume":"4","author":"Mulay","year":"2018","journal-title":"Kidney Dis"},{"key":"B115-20241015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ndt\/gft248","article-title":"Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease","volume":"29","author":"Mulay","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B116-20241015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ki.2013.207","article-title":"NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy","volume":"84","author":"Knauf","year":"2013","journal-title":"Kidney Int"},{"key":"B117-20241015","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ebiom.2019.10.059","article-title":"H19 promote calcium oxalate nephrocalcinosis-induced renal tubular epithelial cell injury via a ceRNA pathway","volume":"50","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"key":"B118-20241015","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/10428194.2020.1846733","article-title":"Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: A cohort study of 468 patients","volume":"62","author":"Medrano","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B119-20241015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.ajkd.2017.02.376","article-title":"Atazanavir-associated crystalline nephropathy","volume":"70","author":"Santoriello","year":"2017","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.11290821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:20Z","timestamp":1786369520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.11290821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":118,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.11290821","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741808747.793592301","asserted-by":"object"}]},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}